Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sonoma Pharmaceuticals Inc SNOA

Healthcare
Sonoma Pharmaceuticals, Inc. is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. The Company's product offerings include Regenacyn Advanced Scar Gel, Regenacyn Plus Scar Gel, Rejuvacyn Advanced Skin Repair Cooling Mist, Pediacyn Skin Care... see more

Recent & Breaking News (NDAQ:SNOA)

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

Business Wire November 24, 2020

ROSEN, RESPECTED INVESTOR COUNSEL, Continues to Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. - SNOA

Newsfile November 24, 2020

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Sonoma Pharmaceuticals, Inc. - SNOA

Business Wire November 24, 2020

Sonoma Pharmaceuticals Reports Second Quarter FY 2021 Financial Results

Business Wire November 20, 2020

Sonoma Pharmaceuticals and MicroSafe Group Announce that Health Canada Authorized Nanocyn® Disinfectant & Sanitizer to be Sold in Canada as a Hard-Surface Disinfectant under COVID-19 Interim Measure

Business Wire September 17, 2020

Sonoma Pharmaceuticals and Te Arai BioFarma Announce Launch of Two New Microcyn® Technology Products in Australia - Nasocyn® Nasal Care and Oracyn® Oral Care

Business Wire September 9, 2020

Sonoma Pharmaceuticals Reports First Quarter 2021 Financial Results

Business Wire August 14, 2020

Sonoma Pharmaceuticals and MicroSafe Group Announce That Microsafe® Disinfectant & Sanitizer Manufactured Using Sonoma's Microcyn® Technology Successfully Passed Material Compatibility Testing for Both Airbus and Boeing Commercial Transport Aircraft

Business Wire July 28, 2020

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2020 Financial Results

Business Wire July 10, 2020

Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn® Disinfectant & Sanitizer Has Received Approval to Be Entered Into the Australian Register of Therapeutic Goods (ARTG) for use against COVID-19

Business Wire May 28, 2020

Sonoma Pharmaceuticals Announces Expanded Distribution Agreement with Brill International S.L. for Europe and approval of new CE Marking for Microdacyn60® Eye Care

Business Wire May 26, 2020

Sonoma Pharmaceuticals Announces Asset Purchase Agreement with Middle East Partner MicroSafe Group

GlobeNewswire February 27, 2020

Sonoma Pharmaceuticals Reports Third Quarter FY 2020 Financial Results

GlobeNewswire February 14, 2020

Sonoma Pharmaceuticals Engages Maxim Group LLC to Explore Strategic Opportunities for its U.S. Dermatology Division

GlobeNewswire January 23, 2020

Sonoma Pharmaceuticals Announces Closing of $1.6 Million Public Offering of Common Stock

GlobeNewswire November 29, 2019

Sonoma Pharmaceuticals Announces Pricing of Approximately $1.6 million Public Offering of Common Stock

GlobeNewswire November 26, 2019

Sonoma Pharmaceuticals Announces Proposed Public Offering of Common Stock

GlobeNewswire November 25, 2019

Sonoma Pharmaceuticals Reports Second Quarter FY 2020 Financial Results

GlobeNewswire November 14, 2019

Sonoma Pharmaceuticals Announces Management Changes

GlobeNewswire October 1, 2019

Sonoma Pharmaceuticals Reports First Quarter FY 2020 Financial Results

GlobeNewswire August 13, 2019